All News

RA.Ow02.jpg

Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters

d MedPage Today

Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.

Read Article
PSORIASIS.LH_.jpg

Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis

d Jack Cush, MD

Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).

Read Article
covid vaccine

FDA Approves First COVID-19 Vaccine

d Jack Cush, MD

Today, the U.S.

Read Article
cigarette,tobacco,smoking,fumes

Passive Smoke Exposure and Rheumatoid Risk

d Jack Cush, MD

A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking, and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive rheumatoid arthritis (RA).

Read Article
Novel tech Sorrento's SOFUSA system, in Phase Ib trial, etanercept given by transdermal nanotopography microneedles to deliver higher concentration of drugs to lymphatic system. An enbrel refractory pt treated & showed 34% improved DAS scores https://t.co/S79HUBT7rE

Links:

Dr. John Cush RheumNow ( View Tweet)

CDC: LA county breakthrough COVID infections: In 43,000 new COVID, 10,895, or 25.3%, occurred in fully vaccinated persons, 1,431, or 3.3%, were in partially vaccinated persons, and 30,801, or 71.4%, were in unvaccinated individuals. https://t.co/gbgaV7THch

Links:

Dr. John Cush RheumNow ( View Tweet)

European Commission has approved bimekizumab (Bimzelx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis. Bimekizumab is a dual IL-17 inhibitor (IL-17A and IL-17F). https://t.co/viRNbx2cbt

Links:

Dr. John Cush RheumNow ( View Tweet)

Most recent numbers from the CDC - The agency said 202,041,893 people had received at least one dose while 171,367,657 people are fully vaccinated as of Tuesday. https://t.co/3rp7QMt84y

Links:

Dr. John Cush RheumNow ( View Tweet)

Safety study of 97 AAV (72 GPA, 25 MPA) pts Rx with Rituxan, median 8 infusions, followed median 3.9 yrs (0.05–4.32). Serious Risks (per 100 Pt-Yrs): serious infections 7.11, cardiac events 5.0, & vascular events 2.37. No deaths related to RTX. https://t.co/WLMQoq79gd

Links:

Dr. John Cush RheumNow ( View Tweet)

Psoriasis Prevalence in adults in the United States is 3.0%, indicating that more than 7.5 million adults 20 years or older have psoriasis. Most common in non-Hispanic White individuals; prevalence has not significantly changed since 2003. https://t.co/3yrlPu1GGi

Links:

Dr. John Cush RheumNow ( View Tweet)

New download available! Cytokine Storm Overview https://t.co/XRlx3OJDeR https://t.co/jq9ZJVx5zH

Links:

Dr. John Cush RheumNow ( View Tweet)
A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive rheumatoid arthritis (RA). https://t.co/szl5L7DGJG https://t.co/yxoEquyLjP

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums--have a question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/QJn6Uo3lbM

Links:

Dr. John Cush RheumNow ( View Tweet)
European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch Now: Using Vitamin D in RA https://t.co/QXYVsa5jzP https://t.co/J9zxOUVRVY

Links:

Dr. John Cush RheumNow ( View Tweet)
Comprehensive, full read overview of (European EADV) S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 1 (classification, Dx, activity) & Part 2 (Treatment) https://t.co/puBCr8VO1I https://t.co/rZKDEsvDzr

Links:

Dr. John Cush RheumNow ( View Tweet)

Breakthrough infections: As of Aug. 9, almost 74% of the 8,054 vaccinated people that were hospitalized with COVID-19 were above the age of 65, according to the U.S. Centers for Disease Control and Prevention. ~20% of those cases ended in deaths https://t.co/jaSmKv5pPS

Links:

Dr. John Cush RheumNow ( View Tweet)

Oligoarticular vs. Polyarticular Psoriatic Arthritis https://t.co/lQVNdmWgMc https://t.co/Kswfkbp5nC

Links:

Dr. John Cush RheumNow ( View Tweet)
The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed. https://t.co/UpQjFgKTpE https://t.co/3dQ2jacwJD

Links:

Dr. John Cush RheumNow ( View Tweet)
https://t.co/wM1iRxtHvk The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/XkJDVwJLwb

Links:

Dr. John Cush RheumNow ( View Tweet)
×